MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
![GlobeNewswire](../../../Content/images/providers/GN.png)
MaxCyte, Inc. (MXCT)
Company Research
Source: GlobeNewswire
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced it has entered into a strategic platform license (SPL) agreement with Legend Biotech, a global leader in cell therapy. Under the terms of the SPL, Legend Biotech obtains a non-exclusive worldwide license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in connection with the research, clinical development and commercialization of cell-based therapeutical products (Licensed Products). In return, MaxCyte will be eligible to receive annual licensing fees and milestones from Legend Biotech during clinical development and, upon successful commercialization, is eligible to receive licensing fees and royalties on net sales of licensed
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services [Yahoo! Finance]Yahoo! Finance
- President of MaxCyte Maher Masoud Buys More Stock [Yahoo! Finance]Yahoo! Finance
- Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why [Yahoo! Finance]Yahoo! Finance
- MaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceGlobeNewswire
MXCT
Earnings
- 5/7/24 - Beat
MXCT
Sec Filings
- 6/24/24 - Form 4
- 6/20/24 - Form 144
- 6/13/24 - Form 4
- MXCT's page on the SEC website